Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
None listed
Sponsors
Archeron Group
Eligibility
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18 and above diagnosed with Breast Cancer. 2. Able to provide blood sample (up to 10ml). 3. Patients ready to give written informed consent and willing to comply with the study protocol.
Exclusion criteria
Exclusion criteria: 1. Patients not eligible to give the required blood sample in the opinion of the investigator. 2. Pregnant or lactating females. 3. Presence of any severe medical or psychological condition or chronic condition/inflammation/infection that in the opinion of the investigator would compromise the patientâ??s safety or successful participation in the study. 4. Patients undergoing chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the specificity and sensitivity of CRISPR-CAS based sensing platform using the BRCA1- Cas12-Strip Assay to detect Breast CancerTimepoint: At Baseline only - onetime assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the Cas12 specificity in combination with gRNA for the detection of single nucleotide polymorphism in breast cancer patientsTimepoint: At Baseline, one-time assessment only. | — |
Countries
India
Contacts
Public ContactMr Tarun Pandotra
Fervor Health Solutions Private Limited
Outcome results
None listed